About Us

Ligon is a pioneering biotechnology company that discovers and develops innovative human medicines targeting important therapeutic needs. Ligon’s cutting-edge technologies discover drugs against previously undruggable disease targets and accelerate the development of more effective therapeutics for patients.

Ligon applies its intellectual property and expertise, including its proprietary Small Molecule Microarray screening platform, to attack high value targets and develop proprietary therapeutics for its own pipeline to treat specific diseases. We focus on diseases for which there are well validated targets which have proven hard to drug. Ligon scientists have demonstrated the ability to discover and validate drugs against the most intractable classes of disease targets, including transcription factors.

Ligon is developing a therapeutic pipeline focused on oncology, coagulation disorders, and antibiotics. In addition to its internal pipeline, Ligon will further expand into other therapeutic areas through collaborations with pharmaceutical and biotechnology industry partners.